Abstract
INTRODUCTION
Aberrant phosphorylation of microtubule associated protein tau (tau) is a hallmark pathology associated with multiple neurodegenerative diseases collectively termed "tauopathies." This process has been shown to be toxic to neurons, and of specific interest, individual phosphorylated residues may be sufficient to drive tau toxicity. One such site is Threonine 175 (Thr 175 ), which has been shown to be phosphorylated (pThr 175 ) in tau protein pathological inclusions in a host of neurodegenerative diseases including amyotrophic lateral sclerosis with cognitive impairment (ALSci), Alzheimer disease, Parkinson disease, Lewy Body dementia, and chronic traumatic encephalopathy (1) (2) (3) (4) . This site of phosphorylation has not been observed in healthy control tissue, or developing fetal brain tissue (where tau protein is physiologically hyperphosphorylated) leading to the current hypothesis that Thr 175 is a tau phosphoepitope associated with disease states only.
In vitro studies using pseudophosphorylated tau protein constructs which mimic pThr 175 (Thr   175 Asp) have demonstrated that the presence of pThr 175 tau is sufficient to induce tau protein aggregate formation in association with increased cell death (5) , and that the induction of pathological tau fibrils in this model is dependent on GSK3b activation that in turn drives phosphorylation of tau protein at Thr 231 (6) . We have also demonstrated that this pathway of pThr 175 induction of GSK3b activation, pThr 231 induction with oligomeric tau formation can be observed across a range of tauopathies (1, 7) , including chronic traumatic encephalopathy (CTE) and CTE with associated motor neuron degeneration (CTE-ALS) (2) . Of note, remarkably similar pathology inclusive of both pThr 175 tau protein and pThr 231 tau protein can be induced by traumatic brain injury (TBI) in a rodent model of moderate TBI (2) . This TBI-induced pathology suggests that the induction of pThr 175 is a critical event in the development of tauopathy after neuronal injury.
The role of pThr 175 tau protein in the induction of a tauopathy may therefore have wide applicability to a range of neurodegenerative processes in which tau deposition is a neuropathological hallmark. Previous studies in rodent models have determined that mutant tau protein expressed in genetic models as well as through adenoviral vectors (AAV9) is capable of inducing tau protein pathology as well as behavioral changes (8) (9) (10) . However, it remains to be determined whether the presence of pThr 175 tau protein alone is sufficient to induce a tauopathy in vivo. In this study, we describe the pathology associated with the expression of a pseudophosphorylated tau protein (human Thr 175 Asp tau) using somatic gene transfer with a rAAV9 adenoviral vector inoculated into the hippocampus of adult Sprague Dawley rats.
MATERIALS AND METHODS
All experimental protocols were approved by the University of Western Ontario Animal Care Committee (AUP #2013-008) in accordance with the policies established in the guide to Care and Use of Experimental Animals prepared by the Canadian Council on Animal Care.
Somatic Gene Transfer
We used a previously described somatic gene transfer technique to express recombinant adeno-associated virus (rAAV9) vectors (9) . All tau constructs were generated from human 2N4R tau as previously described (5). Expressed constructs were as follows: rAAV9 eGFP-tagged wild type human 2N4R tau (wt-human tau), rAAV9 eGFP-tagged Thr 175 Alanine-tau (phosphorylation inhibition), rAAV9 eGFP-tagged Thr 175 Asp tau protein (phosphorylation mimic), rAAV9 eGFP (control). Constructs were expressed bilaterally in the hippocampi of adult, wild-type female Sprague Dawley rats. The proprietary system we used consisted of an AAV9 capsid coat with CAG promoter (hybrid of the cytomegalovirus early enhancer element and chicken b-actin promoter and the slice acceptor of the rabbit b-globulin gene), which is used to drive high levels of gene expression in mammalian expression vectors. The inverted tandem repeats implemented in this system are taken from AAV2, which are more efficient than other AAV serotypes for concatemerizing. The eGFP-tau fusion protein constructs were inserted following the CAG promoter. Vectors were constructed by Vector Biolabs (Philadelphia, PA) and have been reported by other groups (11) . A schematic representation is shown in Supplementary Data Figure S1 .
Surgical Procedures
Two-month old wild type female Sprague-Dawley rats (Charles River, Montreal, Canada) were housed in pairs prior to surgery and randomly assigned to an experimental or control group (n ¼ 10 per group). Food and water were provided ad libitum. Fifteen rats developed mammary or pituitary tumors and were killed or died prior to the 12-month time point. This extent of benign tumor development has been documented previously by others and can occur spontaneously in up to 50% of rats in the Sprague-Dawley line after the age of 6 months (12) . To increase the number of rats for statistical power for imaging studies, a second cohort of 15 additional surgeries were performed to replace the missing rats from each group.
Animals were anesthetized with isoflurane and inserted into a stereotaxic frame. Following standard surgical preparation and a preemptive dose of 0.1 mL/100 g Baytril and 0.1 mL/100 g Meloxicam subcutaneously, a rostrocaudal incision was made along the midline of the scalp, and the subcutaneous tissue and periosteum were elevated to expose the underlying bone. Using Bregma and Lambda as reference points, 4 burr holes were drilled into the skull and rAAV9 vectors were injected bilaterally at 2 sites per hippocampus, at the following coordinates: A/P: À5. (13)). A total volume of 12 lL (3lL per site) was injected over the course of 20 minutes (5 minutes per site) for a total of 1.32 Â 10 10 vector genomes. After injection, the syringe tip remained in place for 2 minutes, was slowly withdrawn and the wound sutured. The vector volume was adopted from previously reported studies utilizing adenoviral vectors to express tau protein in hippocampus (9) . Following recovery from the surgery, rats were singly housed for 1 week before returning to paired housing.
Behavioral Analysis
All rats underwent Morris water maze testing, startle box testing, and open field testing as part of a behavioral battery described in detail in the Supplementary Data Methods.
Open Field Testing
Open field testing was used to determine exploratory behavior and to provide a measure of anxiety-like behavior. As reported previously, animals were placed in a locomotor box (Versamax, Columbus, OH) and allowed to freely explore for 30 minutes while monitored by an overhead camera (14, 15) . Activity was analyzed using ANY-MAZE software version 4.82. The total time spent moving, the distance traveled, as well as the time spent in the center or the periphery of the box was analyzed.
Acoustic Startle Response
The acoustic startle response was used to measure prepulse inhibition, a behavioral measure of sensorimotor gating, shown to be disrupted in many neurodegenerative diseases (16) (17) (18) (19) . Prepulse inhibition is mediated by midbrain circuits, but modulated by the hippocampus, with the CA1 and dentate gyrus having greatest involvement (20, 21) . To measure the acoustic startle response, rats were acclimatized to soundproof startle boxes (Med Associates, Fairfax, VT) with a constant background noise of 65 dB over a 5-minute period. Full details of startle box protocol have been previously published and are reported in the Supplementary Data Methods (22) . Briefly, after acclimatization, rats were exposed to 2 blocks of startle stimuli. Block I consisted of 50 startle stimuli of 20 ms duration and 110 dB intensity. Block II consisted of pseudorandomized trials of the same startle stimuli paired with or without a prepulse stimulus of 4-ms duration at either 75 or 85 dB intensity. Testing was conducted over 3 days to acclimatize the animal to the startle boxes, establish an input/output function, and test the animals.
Morris Water Maze
The Morris Water Maze (MWM) task was used to assess spatial learning and memory under previously reported conditions (15) . Full details are reported in Supplementary Data Methods. Briefly, spatial learning trials were conducted over 4 days in which rats learned which quadrant of the maze held a submerged platform. To test reference memory, a probe trial was conducted on the fifth day of testing (24 hours after the fourth spatial learning trial) where the hidden platform was removed from the pool and the time spent in the target quadrant was analyzed. Another probe trial 7 days after the first probe trial was added to test long-term memory at 6 and 9 months postsurgery. At the 12-month postsurgery time point a reversal learning trial was added where the position of the platform was changed.
Each time point (3, 6, 9, and 12 months after surgery) had a different platform location different from the previous time point. Experiments were performed and the data was collected and analyzed by an individual blinded to the experimental groups. All experiments were carried out during the light cycle.
Neuroimaging
All in vivo imaging data was acquired on an Agilent 9. 
Immunohistochemistry
At 12 months post injection, 4 rats per group were intraperitoneally injected with a lethal dose of Euthanyl and transcardially perfused with heparinized saline (10 units heparin/ mL, 9% NaCl) followed by perfusion fixation with 4% formaldehyde (pH 7.4). Brains were removed and postfixed in 4% formaldehyde for 24 hours before embedding in paraffin wax. Tissue was then serially sectioned at 4-6-lm-thick sections and mounted to microscope slides. Because brains were cut prior to embedding and sectioning, each slide contained 5 sections per animal representing 5 distant points along the rostrocaudal axis.
Immunohistochemistry was conducted to analyze vector expression and the induction of pathology using rabbit anti-GFP (1: 750 titer, Life Technologies, Eugene, OR) and rabbit anti-pThr 231 tau (1: 7500 titer, Thermo Fisher). Antigen retrieval (10 mM sodium citrate, 0.05% Tween 20 pH 6.0) was conducted for all antibodies using a pressure cooker (2100 Retriever; Aptum Biologics, Southampton, UK). Endogenous peroxidase was quenched with 3% hydrogen peroxide (VWR, Mississauga, Canada). Primary antibody incubation was performed at 4˚C overnight in blocking buffer (5% BSA, 0.3% Triton-X 100 in 1Â PBS). After washing, secondary antibody (1: 200 biotinylated IgG) incubation was performed for 1 hour at room temperature in blocking buffer. Antigen: antibody complex was visualized with horseradish peroxidase according to the manufacturer's instructions (Vectastain ABC kit, Vector Laboratories, Burlingame, CA), followed by substrate development with DAB. Counterstaining was performed using Harris hematoxylin.
GFP Expression and Pathology Mapping
Every tenth slide from the serially sectioned brain was stained with rabbit anti-GFP and analyzed for expression. The hippocampus was assessed for GFP expression along its entire rostrocaudal axis. For every slide, the hippocampus was divided into dentate gyrus, CA4, CA3, CA2, CA1, subiculum and fimbria. Expression in each region was graded as present (positive) or absent (negative) for each animal, and the percentage of animals expressing the GFP construct was documented.
For each GFP expressing region, the extent of pathological tau protein deposition and pathology was mapped by probing for GFP and pThr 231 tau protein separately, and then expressed according to the same hippocampal breakdown and positive or negative criteria in each animal for all GFPexpressing regions. Based on the results of the GFP expression mapping, 1 slide per animal was selected for a detailed pathological analysis based on the expression of the GFP construct. The slides that were scored were those showing most intense staining for GFP in the CA2 hippocampal region in each brain. No group expressed more intense GFP than any other. The evaluator (A.M.) remained blinded to the grouping of the rodents until all aspects of the analysis had been completed. 
Colocalization and Fluorescence Staining

Quantification and Statistical Analysis
Caspase-3 Positivity
Randomly selected fields within the GFP-expressing CA2 hippocampal pyramidal layer were photographed by confocal microscopy with a 25Â objective in GFP-expressing CA2 regions for each animal. The total number of GFPexpressing cells, and the number of cleaved caspase-3-positive, GFP-expressing cells were counted and expressed as caspase-3/total cells. Statistical analyses were conducted using SigmaPlot 10.0 software. A 1-way analysis of variance (ANOVA) was conducted following a Shapiro-Wilk test for normality. Post-hoc Tukey test was conducted and a p value of 0.05 or lower was considered significant.
Behavioral Assessments
IBM SPSS Statistics 20 was used for statistical analysis. Data were expressed as group means (groups are defined by the 4 treatments) 6 the standard error of the mean (SEM). Student t-tests, 1-way, and 2-way ANOVA testing were used where appropriate. Repeated measures ANOVA were also used to compare groups. These tests were followed by post hoc tests and Bonferroni corrections. 
RESULTS
GFP Construct Expression in the Hippocampus
Hippocampal GFP expression was observed in all groups throughout the anteroposterior axis of the hippocampus (Fig. 1) . The CA2 subregion revealed GFP-positive staining in pyramidal neurons as well as in projections (neuritic processes) within the stratum radiatum and cell bodies within the stratum oriens in all animals regardless of group, suggesting consistent long-term expression of the adenoviral vector across all subgroups. In regions outside of the CA2, we observed variability in the extent of GFP expression and staining in non-CA2 regions was never as intense as the positive staining in the CA2 region. GFP neuronal expression was also observed in the subcortical white matter just superficial to the hippocampus.
Behavioral Analysis
No behavioral differences were observed between groups (see Supplementary Data Materials) as determined by open field testing, startle box testing, or Morris water maze (Supplementary Data Figs. S2-S5) . Importantly, there were no motor or spatial learning impairments in the Thr 175 Asp-tau group compared to any of the control groups (Fig. 2) .
Imaging
All statistical analysis was performed blinded. ROI analysis was first performed to quantify mean FA and MD within the hippocampus. A 1-way ANOVA was performed to draw statistical comparisons between each group at each time point (1, 3, 6, 9, and 12 months). There were no significant differences (p > 0.05) in FA and MD between groups at each time point. Upon completion of the study, a longitudinal 1-way ANOVA was performed within each group comparing both FA and MD. No significant differences (p > 0.05) were found in each group over the course of the study. Similarly, TBSS was used to analyze whole brain FA and MD maps on a voxelwise basis. While high-resolution structural and diffusion tensor images were acquired (Supplementary Data Fig. S6 ), there were no significant differences between groups at each time point or within groups over time on a voxel-wise basis (p > 0.05).
Tau Protein Pathology In Vivo
Tau-immunoreactive neuronal cytoplasmic inclusions were observed exclusively in the Thr 175 Asp tau-expressing rats in all hippocampal regions expressing GFP constructs. This was evident using either the rabbit anti-GFP (recognizing tau constructs, Fig. 3 ) or the pThr 231 tau antibody (Fig. 4) . In the rAAV9 Thr 175 Asp tau constructs only, we observed axonal beading, fibrils, and tangles (see Fig. 3 for examples as observed using anti-GFP immunohistochemistry). In addition to this, pThr 231 staining revealed fibrillar neuronal inclusions and glial-positive cells in a phenotype resembling coiled bodies (Fig. 4) .
We observed some degree of axonal beading in all groups within GFP-immunoreactive processes, suggesting that this was a nonspecific feature of the invasiveness of the surgery itself. However, no other pathology was observed outside of that found in 
Thr 175 Asp Tau Protein Expressing Cells Are Positive for Cleaved Caspase-3
The number of GFP-positive cells expressing cleaved caspase-3 was calculated as a proportion of the total number of GFP-positive cells in the field of randomly photographed GFP-expressing CA2 region taken by confocal microscopy with a 25Â objective (Fig. 6) 
Activated GSK3b Expression
In the CA2 pyramidal neurons of all animals, activated GSK3b was observed in both the nucleus and cytosol. Due to high levels of immunoreactivity in all animals regardless of group, no difference in the GSK3b localization or apparent expression could be detected between groups (Fig. 7) .
DISCUSSION
We have shown that the expression of Thr Ala, GFP). While we did not observe an upregulation in the expression of activated GSK3b due to its generalized expression, we have previously defined this pathway of pThr 175 tau driving pThr 231 induction in vitro. The evidence of pThr 175 toxicity in this animal model builds on our previous in vitro observation of pThr 175 tau mediated neurotoxicity and confirms that this phosphoepitope on tau protein may be capable of setting off a cascade of phosphorylation events that are toxic in an intact brain (6) .
Additionally, it shows that onset of expression in the adult brain will lead to pathological fibril formation as well as apoptotic cell death. Therefore, the pThr 175 pathology observed in those neurodegenerative diseases that we have thus far investigated, supports a common mechanism of tau mediated neurotoxicity across a broad range of tauopathies (1, 2) .
Although the animal model we utilized in this study did express pathology, it was localized to the discrete region bearing the GFP-tau construct. Most specifically, tau pathology in this experimental model was limited to the hippocampal region CA2, a region for which the behavioral testing paradigm T h r A l a -t a u G F P F FIGURE 2. No significant differences in performance between treatment groups during Morris water maze probe trial day 5. Rats express WT tau (n ¼ 6), Thr 175 Asp-tau (n ¼ 7), Thr 175 Ala-tau (n ¼ 8), or GFP (n ¼ 9). There was no statistically significant difference between construct expressing groups as measured by average swim speed (A), total distance traveled (B), time spent in the platform zone (C), latency to reach platform zone (D), time spent in the area around the platform (E), or latency to the area around the platform during probe trial day 5 at month 12 postsurgery (F). Data are expressed as means 6 SEM.
was insensitive. Moreover, it is also quite likely that the load of tau deposition and the extent of neuronal death or dysfunction was insufficient for a phenotype to be expressed. A similar argument can be made for the failure to observe pathology using high-resolution MRI. To address this, future behavioral studies will employ testing paradigms that are more sensitive to deficits in CA2 (such as social memory) in evaluating Thr 175 Asp tau protein-mediated behavioral changes (24) . With respect to the neuroimaging studies, it is known that ex vivo imaging methods have a much higher resolution than the in vivo imaging used in these studies (25) . As such, future studies using this model will require more sensitive measures of behavior and imaging.
Alternatively, using a genetic model with more widespread expression of Thr 175 Asp tau protein may be a useful tool now that the pathogenicity of this tau protein construct in vivo has been confirmed. This may be the more useful tool for assessing therapeutic potential due to the possibility of a more aggressive pathology and behavioral phenotypes that will be more easily measured over time.
We observed axonal damage in all 4 groups, likely a result of the invasiveness of surgery. Beyond this damage, the Thr Asp tau inoculated subgroup of rats (5) .
We have previously shown that the toxicity observed downstream of Thr 175 phosphorylation relies on increased activation of GSK3b (6) . We propose that phosphorylation of tau protein at Thr 175 may promote a conformational change, deviating from the global hairpin conformation which tau protein has been reported to take in solution (26) .The location of this phosphoepitope on the Pro-rich domain/hinge region of the hairpin suggests that this conformational change is possible based on previous reports of phosphorylation in the proline rich domain (26, 27) . This conformational change will be the focus of future studies. Downstream of global hairpin conformation opening, there are 3 potential mechanisms by which increased GSK3b activation may be induced by tau protein structural change. First, opening of the hairpin may provide increased substrate for GSK3b by exposing more Ser and Thr residues on tau protein. It is known that increasing substrate availability can increase the activity of kinases including GSK3b (28) . Second, opening of the hairpin may expose the proline-rich domain, allowing for tau interactions with other signaling molecules through SH3 homology domains which interact with Fyn kinase (29) . This in turn has been shown to Pseudophosphorylated Thr 175 Tau-Induced Pathology phosphorylate GSK3b at Tyr 216 , enhancing its activity, leading to increased tau phosphorylation in vitro (30) . Finally, opening of the tau hairpin conformation may expose the N-terminal phosphatase activating domain (PAD), consisting of amino acids 2-18. The PAD domain has been shown to directly activate GSK3b-related pathways (31) . While each of these possibilities is dependent on opening of the hairpin loop structure, it is unknown whether the effect of Thr 175 phosphorylation can directly cause an opening of the global hairpin conformation or if this is mediated by a downstream effect. Previous studies of tau protein toxicity in rodent models have not used pseudophosphorylated tau protein, but rather investigated FTDP-17 causing tau mutant variants (G272V, P301L, P301S, V337M, K369I, and R406W) (8, 10, (32) (33) (34) . These studies have reported impaired axonal transport and induction of pathology and increased tau protein phosphorylation in rodent models. Mustroph et al reported behavioral changes observed by Morris water maze when P301L mutant tau was expressed by AAV9 injection into adult rat hippocampus (9) . Notably, mutant tau protein may be more aggressive in nature than pseudophosphorylated tau protein, and the injection sites used by Mustroph et al were different from those utilized in this study.
Given the evidence of toxicity and the mechanism by which this is exerted downstream of Thr 175 tau phosphorylation, the inhibition of GK3b may be a useful therapeutic strategy in neurodegenerative diseases bearing pThr 175 tau protein pathology. The potential efficacy of GSK3b inhibition will be the focus of future studies in animal models of pThr 175 toxicity. There is already evidence of GSK3b inhibition reducing tau protein based pathological processes in vitro (6, 35) and in vivo (36 175 Asp tau inoculated rats (white arrows). In contrast, while diffuse pThr 231 tau protein immunoreactivity was detected in inoculated groups, pathological pThr231-immunoreactive tau inclusions were restricted to the rAAV9 Thr 175 tau inoculated rats. Scale bar ¼ 100 lm for low magnification images and 10-lm high-magnification images. Pseudophosphorylated Thr 175 Tau-Induced Pathology decreased levels of insoluble tau protein and less axonal degeneration after daily intraperitoneal injection of lithium for 30 days (36) . Additionally, a mouse model using 3 mutant tau constructs showed that tau is phosphorylated at sites associated with GSK3b and that chronic GSK3b inhibition using lithium reduced tau aggregation in these strains (37) . In support of the potential role for GSK3b inhibition as a therapeutic strategy, population studies of bipolar disorder patients receiving chronic lithium treatment have reported reduced rates of Alzheimer disease (38, 39) . Taken together, these data suggest that pThr 175 tau protein is capable of inducing fibril formation, tau protein-based pathology, neurotoxicity, and death in vivo. Further investigation using GSK3b inhibitors will determine therapeutic potential to inhibit pThr 175 based tau protein toxicity in vivo and whether this may be effective in human tauopathies. Thr Ala GFP FIGURE 7. Activated GSK3b is expressed in all groups. Nuclear and cytosolic GSK3b expression was observed in GFPexpressing hippocampal neurons in all construct-bearing groups. No inter-group differences were observed. Scale bar ¼ 20 lm.
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